Tagliaferro Francesco Bruno, Orgera Gianluigi, Mascagni Luca, Laurino Florindo, Tipaldi Marcello Andrea, Cariati Maurizio, Rossi Michele
Unit of Interventional Radiology, Sant'Andrea University Hospital, La Sapienza University, Rome, Italy.
Advanced Diagnostic-Therapeutic Technologies Department, ASST Santi Paolo e Carlo, Milano, Italy.
J Vasc Access. 2020 Jan;21(1):79-85. doi: 10.1177/1129729819854593. Epub 2019 Jun 24.
To retrospectively assess the efficacy and safety of FemoSeal vascular closure device to achieve hemostasis following antegrade common femoral artery puncture after lower limb revascularization using vascular sheaths from 5 to 8 Fr.
We reviewed the hemostatic outcome achieved with FemoSeal in 103 consecutive patients (mean age: 69 ± 8 years, 71 males) that undergone to 111 antegrade common femoral artery accesses for percutaneous lower limbs revascularization using 5- to 8-Fr vascular sheaths. We used FemoSeal in an unselected population, without exclusion criteria. The primary outcome was the technical success, meant as achieving complete hemostasis without immediate complications.
Hemostasis was achieved in all 111 puncture sites (100% technical success). We observed eight (7%) puncture site minor complications (hematomas), none of which affecting the patients' outcome or requiring further therapies or increasing the hospital stay. There were no statistically significant differences between the variables potentially related to the occurrence of complications (age, international normalized ratio, platelet count, partial thromboplastin time ratio, body mass index, and common femoral arteries calcification grade) in patients with and without complications. Complications group mean body mass index was 26.4 ± 2.8 kg/m versus non-complications group 26.6 ± 4.4 kg/m, p = 0.92. Mean international normalized ratio and partial thromboplastin time ratio were 1.05 ± 0.01 and 1.05 ± 0.14 versus 1.13 ± 0.2 (p = 0.39) and 1.12 ± 0.23 (p = 0.53), respectively. Common femoral arteries calcification grade was the same (mean: 1, p = 1). Platelet count was 202 × 10/mL ± 66.7 versus 226 × 10/mL ± 91.2, p = 0.55. Mean age was 72.3 ± 10 years versus 72.8 ± 8 years, p = 0.86.
The low rate (7%) and grading of the adverse events, combined with the high technical success rate (100%), in an unselected group of patients treated in daily routine, suggest high safety and efficacy of FemoSeal vascular closure device in antegrade common femoral artery puncture site hemostasis when using vascular sheaths ranging from 5 to 8 Fr. Therefore, FemoSeal could be considered as a first-line hemostasis strategy in such cases.
回顾性评估FemoSeal血管闭合装置在使用5至8F血管鞘进行下肢血管重建术后经股总动脉顺行穿刺实现止血的有效性和安全性。
我们回顾了103例连续患者(平均年龄:69±8岁,男性71例)使用FemoSeal实现止血的结果,这些患者因经皮下肢血管重建术通过股总动脉顺行穿刺111次,使用5至8F血管鞘。我们在未进行选择、无排除标准的人群中使用FemoSeal。主要结局为技术成功,定义为实现完全止血且无即刻并发症。
111个穿刺部位均实现止血(技术成功率100%)。我们观察到8例(7%)穿刺部位轻微并发症(血肿),无一例影响患者结局、需要进一步治疗或延长住院时间。有并发症患者和无并发症患者中,与并发症发生潜在相关的变量(年龄、国际标准化比值、血小板计数、活化部分凝血活酶时间比值、体重指数和股总动脉钙化分级)之间无统计学显著差异。并发症组平均体重指数为26.4±2.8kg/m²,无并发症组为26.6±4.4kg/m²,p = 0.92。平均国际标准化比值和活化部分凝血活酶时间比值分别为1.05±0.01和1.05±0.14,而无并发症组分别为1.13±0.2(p = 0.39)和1.12±0.23(p = 0.53)。股总动脉钙化分级相同(平均值:1,p = 1)。血小板计数分别为202×10⁹/mL±66.7和226×10⁹/mL±91.2,p = 0.55。平均年龄分别为72.3±10岁和72.8±8岁,p = 0.86。
在日常常规治疗的未选择患者组中,不良事件发生率低(7%)且分级低,同时技术成功率高(100%),这表明FemoSeal血管闭合装置在使用5至8F血管鞘时,在股总动脉顺行穿刺部位止血方面具有高安全性和有效性。因此,在这种情况下,FemoSeal可被视为一线止血策略。